Why I Opposed Half-Baked Legalization in Ohio
Legalization should mean everyone has the right to grow, not just some people or corporations with money looking to profit.
The Youth Movement To End The War On Drugs
Most of the information the “D.A.R.E. generation” was taught in school was sensationalized, exaggerated, or simply factually incorrect (typically all three).
Be Honest, Is Your Psychedelic Use Purely “Sacred”?
Isn’t it just as valid and meaningful for psychedelics to be used for diversion, entertainment, relaxation, and adventure?
Coming Out of the Psychedelic Closet
Who am I? How do you answer that question? I’m a mother, a wife, a teacher, a scholar. And I’m also a psychedelic woman.
Envisioning a Sensible Psychedelic Drug Policy
What if honest drug education, harm reduction, long term integration, and acknowledging risks, took the place of propaganda?
Psychedelics & Sexual Healing: A Talk with Dee Dee Goldpaugh
So much of the conversation surrounding sex, like that surrounding drugs, is fear-based and chock full of negativity.
As COMPASS Pathways continues its attempts to build a psychedelic monopoly, Usona Institute keeps publishing open research
Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.
Hamilton Morris Hired by Psilocybin Startup COMPASS Pathways, Ends “Hamilton’s Pharmacopeia” On Vice
Hamilton Morris, the creator of Vice’s “Hamilton’s Pharmacopeia,” will cease working with Vice on the show following the third season. He has joined psychedelic pharmaceutical corporation COMPASS Pathways as a chemistry consultant.
The Third Wave’s Paul Austin Has Been Accused of Stealing Information For His Psychedelic Provider Directory
The Third Wave copied information from Psychedelic.Support and MAPS Integration List without permission to use for its own directory.
ATAI Life Sciences Company, EmpathBio, Dives Into MDMA Derivatives, Calls MAPS’ Approach “MDMA 1.0”
Through EmpathBio, ATAI Life Sciences says it will develop “safer” MDMA derivatives for patients with PTSD and calls the Multidisciplinary Association for Psychedelic Studies' (MAPS) approach "MDMA 1.0." MAPS' executive director, Rick Doblin, says that if that's the case, ATAI is "MDMA 0.5."